Jump to content

KRAS. Help on the way?


Recommended Posts

Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target [1]. In presenting positive data from a Phase I dose-escalation study of AMG 510, an oral small molecule inhibitor of KRAS G12C. AMG 510 achieved a 50% response rate among non-small cell lung cancer (NSCLC) patients expressing the KRAS G12C mutation.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.